🔓
Sign in as a Member to unlock the full view of S.3267. · Full carveout list, all affected companies, party defectors, and 30-day trade predictions.
Become a Member$24.50/mo already a Member? Sign in →
S.3267 · 119TH CONGRESS

ASAP Act

Status
In Committee
Latest Action
2025-11-20
Sponsor
Collins, Susan M. (R-Maine)
Official Source
Investability
0/100
Stage
COMMITTEE
Related Bills
1
Full Text
2,484 chars
Alive
Yes

What This Bill Does · Plain English

Summary
Plain-English summary not yet available for this bill. Check back after our next analysis run.

Action Timeline

2025-11-20
Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S8278-8279)
2025-11-20
Introduced in Senate

Frequently Asked Questions

Did S.3267 pass?
S.3267 is still alive. Current stage: COMMITTEE. Pass likelihood: pending.
Who sponsored S.3267?
S.3267 was sponsored by Susan M. Collins (R-Maine).

Full Bill Text

119 S3267 IS: Alzheimer's Screening and Prevention Act U.S. Senate 2025-11-20 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. II 119th CONGRESS 1st Session S. 3267 IN THE SENATE OF THE UNITED STATES November 20, 2025 Ms. Collins (for herself, Ms. Cortez Masto , Mrs. Capito , and Mr. Warner ) introduced the following bill; which was read twice and referred to the Committee on Finance A BILL To amend title XVIII of the Social Security Act to provide for Medicare coverage of blood-based dementia screening tests. 1. Short title This Act may be cited as the Alzheimer's Screening and Prevention Act or the ASAP Act . 2. Medicare coverage of Alzheimer’s disease and related dementias early detection screening tests (a) Coverage Section 1861 of the Social Security Act ( 42 U.S.C. 1395x ) is amended— (1) in subsection (s)(2)— (A) in subparagraph (JJ), by striking the semicolon at the end and inserting ; and ; and (B) by adding at the end the following new subparagraph: (KK) Alzheimer’s disease and related dementias early detection screening tests (as defined in subsection (nnn)); and (2) by adding at the end the following new subsection: (nnn) Alzheimer’s disease and related dementias early detection screening tests The term Alzheimer’s disease and related dementias early detection screening test means a test furnished to an individual for the detection of the pre-symptomatic and early stage of Alzheimer’s disease or related dementias on or after January 1, 2028, that— (1) is cleared under section 510(k), classified under section 513(f)(2), or approved under section 515 of the Federal Food, Drug, and Cosmetic Act; and (2) is— (A) a genomic sequencing blood or blood product test; or (B) such other equivalent test, including a single-analyte test, blood test analysis of cell-free nucleic acids, multiplex panel test, whole genome sequencing, protein expression, whole exome, whole transcriptome, and medical imaging (which are based on blood, blood products, tissue, urine or other biospecimen), as the Secretary determines appropriate in providing results comparable to those obtained with a test described in subparagraph (A). . (b) Payment Section 1833(h)(1)(A) of the Social Security Act ( 42 U.S.C. 1395l(h)(1)(A) ) is amended by inserting Alzheimer’s disease and related dementias early detection screening tests under section 1861(nnn) and after including .
🔒 GovGreed Pro · Trading Intelligence on S.3267 Get Access — $24.50/mo
Loading intelligence layer…
Bill text sourced from GovInfo.gov · public domain · last updated 2026-09-14. Plain-English summary, score breakdown, and trading-intelligence panels are GovGreed-original analysis derived from STOCK Act filings, SEC Form 4 disclosures, FEC contributions, and Senate LDA lobbying reports — all publicly filed federal records. GovGreed is not affiliated with the U.S. Government. Not financial advice. [live render]